Skip to main content

Table 2 Evaluation of therapeutic effect of milk antibody treatment in 18 patients in test group.

From: Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins: results of an open-labelled pilot study

Patient

ID

Eval

Point1)

ACR2)

Criteria

DAS28-ESR

Remarks of improvements

DRB1-

Allele

   

Pre

Post

Δ

EULAR3)

GI4)

General condition5)

  

Responders

3709

8

20

6.01

3.47

2.54

Moderate

C (+)

Fatigue, Anemia, Weight loss

0101

0405

3188

8

20

6.31

4.82

1.49

Moderate

C (+)

ADL

0405

0404

4119

6

50

4.61

3.39

1.22

Moderate

(/)

Range of motion

0901

1406

198

6

<20

8.02

7.13

0.89

No

C (+)

Fatigue, Anemia

0803

1401

5284

5

<20

4.32

3.07

1.25

Good

C (+)

Unhealthy feeling

0410

1502

10572

3

<20

6.12

6.08

0.04

No

C (+)

Appetite, Sleep

1302

1406

1316

3

<20

4.34

4.21

0.13

No

C (+)

Fatigue

ND

ND

3240

3

<20

5.29

4.63

0.66

Moderate

D (+)

Unhealthy feeling

0405

1202

Ave

5.3 ± 2.1

 

5.63 ± 1.26

4.66 ± 1.43

0.97 ± 0.87

 

(7/7)

   

Pre vs. Post

   

P < 0.01

 

P < 0.01

   

Partial responders

169

2

<20

5.26

6.22

-0.96

No

(/)

Fatigue, Intra-articular effusion

0901

-

511

1

<20

8.15

7.85

0.30

No

D (+)

Range of motion

0405

1101

Ave

1.5 ± 0.7

 

6.75 ± 2.10

7.04 ± 1.15

-0.33 ± 0.89

 

(1/1)

   

Non-Responders

9291

2

<20

4.70

5.04

-0.34

No

C (+)

-

0803

1501

3007

1

<20

4.44

5.85

-1.41

No

(/)

-

1101

1502

2264

1

<20

8.00

7.86

0.14

No

C (+)

-

0405

-

721

1

<20

6.33

6.29

-0.04

No

C (+)

-

0405

1501

7785

0

<20

6.22

7.58

-1.36

No

C (-)

Edema at lower thigh

0901

1501

2110

0

<20

ND

ND

ND

ND

C (-)

-

0405

1502

8861

0

<20

4.01

5.68

-1.67

No

C (-)

-

0901

1501

10164

0

<20

4.45

4.94

-0.49

No

(/)

-

0405

1501

Ave

0.6 ± 0.7

 

5.45 ± 1.44

6.18 ± 1.15

-0.73 ± 0.74

 

(3/6)

   

Pre vs. Post

   

NS

 

NS

   

Responder vs. Non-Responder

NS

P < 0.05

      
  1. 1) Number of categories among 8 categories gained more than 20% improvement. 2) American College of Rheumatology, 3) European League Against Rheumatism response criteria using DAS28-ESR. 4) Gastrointestinal disorder, C: Constipation, D: Diarrhea, (+): improved, (-): not improved, (/): no GI disorder. 5) ADL: activities of daily living.
  2. ND: Not determined, NS: Not significant.